-
Why Immunotherapy Isn’t Perfect & How Scientists Are Working to Fix It
The human immune system is an intricate web of checks and balances that usually excels at detecting and destroying foreign invaders, such as bacteria and viruses, while protecting healthy tissue. But...
IN THE SPOTLIGHT
-
Small Cell SMASHERS Fireside Chat with Dr. Misty Shields
This special edition of the Small Cell SMASHERS features Misty Shields, MD, PhD, as a guest instead of her usual role as host. Dr. Shields is a thoracic medical oncologist... -
Explaining BiTE® Therapy
A bi-specific T-cell engager (BiTE®) is a new type of engineered molecule used for the treatment of cancer. These molecules harness and activate T-cells, which are involved in the... -
Biggest News from Berlin: Research Highlights from ESMO
Lung cancer research was in the spotlight at the European Society for Medical Oncology (ESMO) meeting held October 17-21, 2025, in Berlin, Germany. With approximately 30,000... -
The Future of Lung Cancer Starts Here
For more than two decades, LUNGevity Foundation has been a leader in advancing lung cancer research. Since 2002, we have invested $55+ million in more than 200 research projects... -
SCLC Virtual Meetup
SCLC patients/survivors - Join us the 3rd Wednesday of every month to c onnect with others who share common experiences and build your community. Register in advance for this... -
Small Cell SMASHERS Fireside Chat with Dr. Trudy Oliver
In November, Trudy Oliver, PhD, professor of pharmacology and cancer biology at Duke University School of Medicine and Duke Cancer Institute, discussed the origins of small cell... -
Celebrating Progress in Lung Cancer: From Detection to Survivorship
Over the past twenty years, lung cancer research and care have entered a new era. One filled with hope, innovation, and progress that is transforming what it means to face a lung... -
Small Cell SMASHERS Fireside Chat: Who's Up Next?
Small Cell SMASHERS Fireside Chat with Dr. Eric Singhi Join us for a YouTube Live on Friday, February 6, with Eric Singhi, MD, assistant professor, University of Texas MD Anderson... -
Small Cell SMASHERS Fireside Chat: Dr. Toby Campbell
In this Facebook Live on Tuesday, October 14, Toby Campbell, MD, MS, thoracic medical oncologist and chief of palliative care at the University of Wisconsin Health, discussed...
Why Immunotherapy Isn’t Perfect & How Scientists Are Working to Fix It
Why Immunotherapy Isn’t Perfect & How Scientists Are Working to Fix It
The human immune system is an intricate web of checks and balances that usually excels at detecting and destroying foreign invaders, such as bacteria and viruses, while protecting healthy tissue. But sometimes, the checks and balances get confused and stop the immune system from doing what’s right—such as killing tumor cells. Tumor cells are good at confusing the immune system because they originate from our healthy cells. They can often avoid detection by immune cells. Through several…
New Horizons in Immunotherapy: Lung Cancer Highlights from the 2025 SITC Meeting
New Horizons in Immunotherapy: Lung Cancer Highlights from the 2025 SITC Meeting
The Society for Immunotherapy of Cancer (SITC) celebrated their 40th anniversary at their annual meeting in National Harbor, Maryland from November 5-9, 2025. The meeting focused on multidisciplinary research aiming to leverage the immune system to improve outcomes for cancer patients, including several exciting areas of growth in lung cancer-directed immunotherapy.Tumor Imaging is Growing More Powerful Advanced imaging techniques are poised to change how we understand and treat…
The Future of Lung Cancer Starts Here
The Future of Lung Cancer Starts Here
For more than two decades, LUNGevity Foundation has been a leader in advancing lung cancer research. Since 2002, we have invested $55+ million in more than 200 research projects, helping to build a robust pipeline of discoveries in early detection, treatment innovation, and health equity.Once again, LUNGevity is ready to open our annual grant cycle in 2026 with five research programs designed to address the most pressing challenges in lung cancer care. In addition, these grants ensure the…
Biggest News from Berlin: Research Highlights from ESMO
Biggest News from Berlin: Research Highlights from ESMO
Lung cancer research was in the spotlight at the European Society for Medical Oncology (ESMO) meeting held October 17-21, 2025, in Berlin, Germany. With approximately 30,000 attendees from over 100 countries, this meeting gathered an international audience of clinicians, researchers, patient advocates, and representatives from the healthcare industry to discuss cutting-edge cancer research and share practice-changing clinical trial data. We saw data from studies that aim to build upon…
Small Cell SMASHERS Fireside Chat with Dr. Misty Shields
Small Cell SMASHERS Fireside Chat with Dr. Misty Shields
This special edition of the Small Cell SMASHERS features Misty Shields, MD, PhD, as a guest instead of her usual role as host. Dr. Shields is a thoracic medical oncologist, assistant professor of clinical medicine, adjunct assistant professor of medical and molecular genetics, and associate member of experimental and developmental therapeutics at Indiana University School of Medicine and Indiana University Health Physicians. Dr. Shields discusses her American Society of Clinical Oncology (…
Small Cell SMASHERS Fireside Chat with Dr. Trudy Oliver
Small Cell SMASHERS Fireside Chat with Dr. Trudy Oliver
In November, Trudy Oliver, PhD, professor of pharmacology and cancer biology at Duke University School of Medicine and Duke Cancer Institute, discussed the origins of small cell lung cancer (SCLC) and its impact on plasticity.Moderated by Dr. Misty Shields, Indiana University School of Medicine, and LUNGevity’s Ann Fish-Steagall, SVP of Patient Services and Health Care Delivery, this monthly virtual series highlights the latest discoveries and breakthroughs for SCLC.
LUNGevity Foundation Invests $1.2 Million to Fuel Next Generation of Lung Cancer Research
LUNGevity Foundation Invests $1.2 Million to Fuel Next Generation of Lung Cancer Research
LUNGevity Foundation announced $1.2 million in research awards that are designed to strengthen the lung cancer workforce and accelerate progress across the lung cancer continuum—from early detection to treating advanced disease.“Today’s research is tomorrow’s cure. If we want to see continued breakthroughs and advancements in lung cancer, we must secure a strong pipeline of researchers dedicated to improving outcomes for people with lung cancer,” said Upal Basu Roy, PhD, MPH, Executive Director…
Celebrating Progress in Lung Cancer: From Detection to Survivorship
Celebrating Progress in Lung Cancer: From Detection to Survivorship
Over the past twenty years, lung cancer research and care have entered a new era. One filled with hope, innovation, and progress that is transforming what it means to face a lung cancer diagnosis. From groundbreaking early detection efforts to life-extending treatments, each step forward represents years of collaboration between researchers, patients, and others in the lung cancer community.Today, LUNGevity celebrates five exciting areas of progress that highlight the incredible strides made…
Small Cell SMASHERS Fireside Chat: Dr. Toby Campbell
Small Cell SMASHERS Fireside Chat: Dr. Toby Campbell
In this Facebook Live on Tuesday, October 14, Toby Campbell, MD, MS, thoracic medical oncologist and chief of palliative care at the University of Wisconsin Health, discussed palliative care in small cell lung cancer.Moderated by Misty Shields, MD, PhD, IU Health, and LUNGevity’s Ann Fish-Steagall, RN, BSN, SVP of Patient Services and Health Care Delivery, the monthly Small Cell SMASHERS series highlights the latest discoveries and breakthroughs for SCLC.
Small Cell SMASHERS Fireside Chat: Dr. Sonam Puri
Small Cell SMASHERS Fireside Chat: Dr. Sonam Puri
In this Facebook Live from September 30, Sonam Puri, MD, Department of Thoracic Oncology at H. Lee Moffitt Cancer Center, discusses the importance of real-world data for treating small cell lung cancer.Moderated by Misty Shields, MD, PhD, IU Health, and LUNGevity’s Ann Fish-Steagall, RN, BSN, SVP of Patient Services and Health Care Delivery, the monthly Small Cell SMASHERS series highlights the latest discoveries and breakthroughs for SCLC.
Why Do Some People Who Have Never Smoked Get Lung Cancer?
Why Do Some People Who Have Never Smoked Get Lung Cancer?
As tobacco use has declined in recent years, we have seen a new demographic of lung cancer patients emerge. Lung cancer in individuals who have never smoked (LCINS) is becoming more common. These people are often younger women with no history of tobacco exposure.Researchers are working to understand the needs of this growing population by identifying other risk factors for lung cancer, such as family history and environmental exposures. They are also studying the molecular underpinnings of this…
Hot Topic Highlights: 2025 Small Cell Lung Cancer Meeting
Hot Topic Highlights: 2025 Small Cell Lung Cancer Meeting
Read time: 6 minutes. April turned out to be an exciting month for lung cancer science. First, we attended the 2025 Small Cell Lung Cancer (SCLC) Hot Topic Meeting held in New York from April 2-4, then the American Association for Cancer Research (AACR) Annual Meeting in Chicago from April 24-30.The SCLC Hot Topic Meeting, hosted by the International Association for the Study of Lung Cancer, has become one of our favorite science meetings. Held at the Memorial Sloan Kettering…
Conversations that Count: Transforming Lung Cancer Care Through Insight and Innovation
Conversations that Count: Transforming Lung Cancer Care Through Insight and Innovation
The LUNGevity Conversations that Count speaker series offers an opportunity to stay informed, engage in critical discussions, and learn from top experts revolutionizing lung cancer care for underserved populations. The series is intended for healthcare professionals, community health equity champions, and anyone interested in equitable access to healthcare. In February, we welcomed Randi Williams, PhD, MPH, of the Lombardi Comprehensive Cancer Center at Georgetown University Medical Center…
Small Cell SMASHERS Fireside Chat: Dr. Christopher Kniese
Small Cell SMASHERS Fireside Chat: Dr. Christopher Kniese
On Friday, March 14, Christopher Kniese, MD, of IU Health, discussed the role of pulmonologists in SCLC, why the right diagnosis is key, logistics and importance of a bronchoscopy/biopsy, pulmonary rehab, and other topics.Moderated by Misty Shields, MD, IU Health, and LUNGevity’s Ann Fish-Steagall, SVP of Patient Services and Health Care Delivery, this monthly virtual series highlights the latest discoveries and breakthroughs in SCLC.
Small Cell SMASHERS Fireside Chat: Drs. Baine and Rekhtman
Small Cell SMASHERS Fireside Chat: Drs. Baine and Rekhtman
On Friday, February 28, Drs. and Rekhtman of Memorial Sloan Kettering Cancer Center joined us on Facebook Live to discuss the role of pathologists in SCLC, why the right diagnosis is key, and the logistics and importance of biopsies. They explained forms of SCLC such as atypical, transformed, and RB proficient.Moderated by Misty Shields, MD, PhD, IU Health, and LUNGevity’s Ann Fish-Steagall, SVP of Patient Services and Health Care Delivery, this monthly virtual series highlights the latest…
Small Cell SMASHERS Fireside Chat: Dr. Mya Tran
Small Cell SMASHERS Fireside Chat: Dr. Mya Tran
Mya Tran, PharmD, BCOP, joined us in January to discuss what people should expect during treatment for small cell lung cancer (SCLC), managing side effects related to SCLC therapy, as well as the importance of genomics and its role in molecularly informed clinical trials for SCLC. Moderated by Dr. Misty Shields, IU Health, and LUNGevity’s Ann Fish-Steagall, SVP of Patient Services and Health Care Delivery, this monthly virtual series highlights the latest discoveries and breakthroughs in SCLC.…
Treating Small Cell Lung Cancer: 2025 and Beyond
Treating Small Cell Lung Cancer: 2025 and Beyond
Read time: 2 minutes. Researchers have been trying to find new ways to treat small cell lung cancer (SCLC) for a long time. Those efforts are starting to pay off in big ways. Join Stephen Liu, MD, of Georgetown Lombardi Comprehensive Cancer Center, and Amy Moore, PhD, of LUNGevity Foundation, as they walk us through the treatment options for SCLC, including exciting breakthroughs on the horizon.This video was part of LUNGevity’s International Lung Cancer Survivorship Conference…
Real-World Examples of Patient Involvement in Designing Clinical Trials
Real-World Examples of Patient Involvement in Designing Clinical Trials
Read time: 2 minutes.Here we present the final video in our three-part series about how patients and researchers can work together to develop clinical trials. In the video below, LUNGevity again partnered with Rising Tide for Clinical Cancer Research to illustrate the power of having patients contribute to the research process. We use a real-world example to learn about patient-researcher collaborations through the POSITIVE study, a breast cancer-focused clinical trial. You can…
Developing Clinical Trials that Account for the Realities of Patient Life
Developing Clinical Trials that Account for the Realities of Patient Life
Read time: 2 minutes. We are pleased to continue our three-part series about how patients and researchers can work together to develop clinical trials. In this second video, LUNGevity again partnered with Rising Tide for Clinical Cancer Research to show how researchers and patient advocates can be empowered with tools to create clinical trials that resonate with patients and address the key issues they care about. If you missed the first video, How Can Patients…
The 5 Most Popular Lung Cancer Blogs From 2024
The 5 Most Popular Lung Cancer Blogs From 2024
Read time: 3 minutes. Throughout 2024 we published blogs sharing scientific meeting recaps, educational content, personal stories, treatment news, and so much more. Below are the most popular articles we published in 2024. If you’re looking for survivor features and personal stories, you can see all the lung cancer survivors we highlighted in 2024 right here. 2024 ASCO: Highlights of Lung Cancer Research In June, we recapped the annual American Society of…
Research Milestones: Celebrating LUNGevity’s 2024 Research Awards
Research Milestones: Celebrating LUNGevity’s 2024 Research Awards
LUNGevity had a tremendous year supporting impactful research in 2024. In addition to our existing portfolio of ongoing research grants, we issued several new research awards in 2024. All of these awards are in strategic areas of research that are likely to move the dial for people living with lung cancer today and those who will be diagnosed in the future. Below are more details about the research projects we recently announced funding for. LUNGevity Supports 10 New Research…
Celebrating 20 Years of Progress in Lung Cancer Research and Treatment
Celebrating 20 Years of Progress in Lung Cancer Research and Treatment
Read time: 5 minutes.This year marks 20 years since researchers made a key discovery that changed the face of lung cancer research and treatment. By uncovering EGFR’s role in lung cancer, researchers developed a new class of drugs—targeted therapies—designed to target specific mutations in lung cancer cells while leaving healthy cells unharmed. As we’ve welcomed this era of precision medicine, we’ve also benefited from other treatment progress in lung cancer—including the development…
Small Cell SMASHERS Fireside Chat: Dr. Triparna Sen
Small Cell SMASHERS Fireside Chat: Dr. Triparna Sen
Triparna Sen, PhD, Icahn School of Medicine at Mount Sinai, New York, joined us for our September Small Cell SMASHERS Facebook Live event. Dr. Sen discussed the biology and the role of biomarkers in small cell lung cancer. Moderated by Dr. Misty Shields, IU Health, and LUNGevity’s Ann Fish-Steagall, SVP of Patient Services and Health Care Delivery, this monthly virtual series highlights the latest discoveries and breakthroughs in small cell lung cancer (SCLC).
Small Cell Lung Cancer: Highlights from WCLC and ESMO 2024
Small Cell Lung Cancer: Highlights from WCLC and ESMO 2024
This is the second blog in our series of updates from the World Conference on Lung Cancer (WCLC), held in San Diego from September 7-10, and the European Society for Medical Oncology (ESMO) conference, held in Barcelona from September 13-17. This update focuses on small cell lung cancer (SCLC), which is seen in 15% of people diagnosed with lung cancer. You can read the other update blogs from these fall science meetings: Metastatic NSCLC Highlights Early-Stage and Locally…
Screening and Early Detection of Lung Cancer: Highlights from WCLC and ESMO 2024
Screening and Early Detection of Lung Cancer: Highlights from WCLC and ESMO 2024
Lung cancer screening and early detection were major topics of discussion at the World Conference on Lung Cancer (WCLC), held in San Diego from September 7-10, and the European Society for Medical Oncology (ESMO) conference in Barcelona from September 13-17. This fourth and final blog in our series of updates summarizes highlights from these discussions. You can read the other update blogs from these fall science meetings: Metastatic NSCLC Highlights Small Cell Lung Cancer…
How Do Drugs Get Approved (and Fast-Tracked) by the FDA?
How Do Drugs Get Approved (and Fast-Tracked) by the FDA?
Read time: 5 minutes. This is Part 3 in our series on how drugs get approved to treat lung cancer. Part 1: Understanding Clinical Trials - Why Are They Important for Drug Development? Part 2: How We Define Success for a Clinical Trial The United States federal government aims to regulate prescription drugs to ensure people are receiving medication that’s safe and effective. Every prescribed drug in the U.S. has gone through a rigorous testing process that can…
How We Define Success for a Clinical Trial
How We Define Success for a Clinical Trial
Read time: 6 minutes. This is Part 2 of 3 in our series on how drugs get approved to treat lung cancer. Make sure to read Part 1 on the phases of clinical trials and why they are important for new drug development. We all want a treatment for lung cancer that is completely safe and entirely effective. While researchers are working toward that goal, the reality is we aren’t there yet. Every treatment we are considering comes with potential benefits and side effects. The…
Understanding Clinical Trials: Why Are They Important for Drug Development?
Understanding Clinical Trials: Why Are They Important for Drug Development?
Read time: 3 minutes.This is Part 1 in a 3-part series explaining how new drugs and treatments get approved to treat lung cancer. Parts 2 and 3 will be published in the coming weeks.Have you ever wondered how a new medicine or drug to treat lung cancer is brought to the people who need it? That’s what clinical trials help us do.According to the National Cancer Institute, a clinical trial is a type of research study that tests how well new medical approaches (such as screening tests, prevention…
Countdown to ILCSC24: Bringing the World’s Experts Right to Your Living Room
Countdown to ILCSC24: Bringing the World’s Experts Right to Your Living Room
Read time: 3 minutes. One of LUNGevity’s two flagship survivorship events, the International Lung Cancer Survivorship Conference (ILCSC), is being held virtually September 20 – 21, 2024. This is a free, online event that allows people with lung cancer and caregivers from around the world to join from the comfort of their own homes and hear from a star-studded lineup of lung cancer experts discussing the latest advances in research and treatment. You can register today for…
How Can Patients and Researchers Design Clinical Trials Together?
How Can Patients and Researchers Design Clinical Trials Together?
Read time: 2 minutes. Traditionally, people associate getting involved in lung cancer research with enrolling in a clinical trial. But most don’t realize they can also partner with researchers behind the scenes and get involved in designing clinical trials. In the first of a three-part series, Rising Tide Foundation for Clinical Cancer Research has partnered with LUNGevity to understand the role people with lung cancer can play in developing clinical trials. Through panelist…